Suppr超能文献

建立链激酶第三国际标准的国际协作研究。

International collaborative study to establish the 3rd International Standard for Streptokinase.

作者信息

Sands D, Whitton C M, Longstaff C

机构信息

Informatics Division, National Institute for Biological Standards and Control, Potters Bar, UK.

出版信息

J Thromb Haemost. 2004 Aug;2(8):1411-5. doi: 10.1111/j.1538-7836.2004.00814.x.

Abstract

An international collaborative study was organized to calibrate a replacement for the current (2nd) International Standard (IS) for Streptokinase, stocks of which are almost exhausted. Two candidate preparations were assayed against the 2nd IS in a study involving 16 laboratories in 12 countries: preparation 88/824 (coded B), and preparation 00/464 (C and D, coded duplicates). Laboratories could use two methods provided, either a fibrin clot lysis assay or a solution chromogenic method, or an in-house method. Laboratories were encouraged to perform more than one method if possible. With the exception of one laboratory which gave outlying results for preparation 00/464, there was good agreement within and between laboratories and no significant differences between potencies using the different methods employed. This study demonstrates that a solution chromogenic assay is an acceptable format for potency determination of the streptokinase preparations in this study and fibrin is not necessary. It has now been agreed that a solution chromogenic plasminogen activation assay replace the current euglobulin reference method for streptokinase activity determination in the European Pharmacopoeia. Study participants, SSC of the International Society on Thrombosis and Haemostasis and the Expert Committee on Biological Standardization (ECBS) at the World Health Organization approved preparation 00/464 (C,D in the study) as the 3rd IS for Streptokinase with a potency of 1030 IU per ampoule.

摘要

组织了一项国际合作研究,以校准链激酶现行(第2版)国际标准品(IS)的替代物,该标准品库存几乎耗尽。在一项涉及12个国家16个实验室的研究中,对两种候选制剂与第2版IS进行了测定:制剂88/824(编码为B)和制剂00/464(C和D,编码为重复样品)。实验室可以使用提供的两种方法,即纤维蛋白凝块溶解试验或溶液显色法,或内部方法。鼓励实验室尽可能采用多种方法。除一个实验室给出制剂00/464的异常结果外,各实验室内部及之间的结果一致性良好,使用不同方法测定的效价无显著差异。本研究表明,溶液显色法是测定本研究中链激酶制剂效价的可接受形式,无需纤维蛋白。现已达成一致,溶液显色纤溶酶原激活试验将取代欧洲药典中现行的测定链激酶活性的优球蛋白参考方法。研究参与者、国际血栓与止血学会的SSC以及世界卫生组织生物标准化专家委员会(ECBS)批准制剂00/464(研究中的C、D)作为链激酶的第3版IS,每安瓿效价为1030 IU。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验